Company intelligence / Profile preview

XWPharma

Wuhan Shi, Hubei Sheng, Chinaxwpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

XWPharma has advanced its flagship sleep program valiloxybate from preclinical to Phase 3-ready and its second clinical program XW10508 has completed Phase 1. Initial results for XW10508 were anticipated in early 2022, with plans to progress to Phase 2a testing.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

XW10508

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on XWPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XWPharma.

Explore the full profile